The advanced understanding of the physiology of the cardiovascular system and the mechanisms of disease progression has been central to our research since the inception of the William Harvey Research Institute by Sir John Vane in 1986.
Vascular pharmacology and inflammation
These programmes investigate mechanisms of vascular homeostasis in inflammation (Thiemermann, Solito, Corder, Hinds, Pearse), acute & chronic renal disease, platelet biology (Warner) and generate candidate molecules (Ahluwalia, Hobbs, Caulfield).
Regenerative cellular therapies
These include innovative cellsheets and new EU-funded trials 11m for vascular disease prevention and treatment (Suzuki, Xiao, Yashiro, and Mathur). Recently a cross-WHRI initiative led by Dunkel with Tinker is the development of a new Human Laboratory for inducible pluripotent stem cells as models of human disease for both functional and pharmacological testing of endocrine and CV disorders.
Innate and adaptive immune responses in CV Disease
These processes are known to play a key role in the pathogenesis and perpetuation of a number of cardiovascular diseases, including heart transplant rejection, atherosclerosis and hypertension. Under the leadership of Marelli-Berg with Peretti and Longhi we are investigating the immunological cellular and molecular mediators of these conditions.